Search Results
Your search for The ASCO matches 21137 pages
Showing 1301 - 1350President’s Cancer Panel Report Highlights Opportunities to Accelerate Progress Toward the National Cancer Plan
A new report from the President’s Cancer Panel offers recommendations in five priority areas to accelerate progress toward implementing the National Cancer Plan and achieving the Biden-Harris Administration’s Cancer Moonshot goal of ending cancer as we know it. The report, delivered to President...
Exposure to Secondhand Smoke During Chemotherapy May Decrease Treatment Efficacy in Patients With Head and Neck Cancer
Researchers have found that exposure to secondhand smoke during treatment with cisplatin may reduce its effectiveness in patients with head and neck cancer, even if they don’t have a history of smoking, according to a recent study published by Sadhasivam et al in the International Journal of...
U.S. Individuals With Incarceration History May Have Lower Likelihood of Undergoing Cancer Screenings
Investigators have found that U.S. individuals with a history of incarceration may have worse access to and receipt of breast cancer and colorectal cancer screenings compared with those without a history of incarceration, according to a recent study published by Zhao et al in JAMA Health Forum....
Celebrating Advances in Cancer Care and a Look at How AI Is Revolutionizing Oncology
For the third year in a row, more than 250 leaders in cancer care, including cancer center directors, physicians, scientists, ethicists, journalists, public officials, and patient advocates, gathered at the Richard Nixon Presidential Library and Museum in Yorba Linda, California, to attend the...
Psychological Distress May Contribute to Cancer Treatment Delays
Researchers have found that psychological distress may contribute to delayed cancer treatment, according to a recent study published by Frosch et al in Supportive Care in Cancer. Background Prior research has shown that delays in initiating cancer therapy may be increasing, and these delays can...
Gene Signature May Predict Response to Combination Therapy in Patients With NSCLC
Researchers have identified a set of 140 genes that may help predict disease-free survival in patients with non–small cell lung cancer (NSCLC) treated with a combination of immunotherapy and low-dose radiation, according to a recent study published by Altorki et al in Cell Reports Medicine. The...
Patients With Advanced Breast Cancer May Gain Multiple Benefits From Exercise as Part of Palliative Care
Although current ASCO guidelines recommend exercise for patients with breast cancer during adjuvant therapy with curative intent, the guidelines state that more study is needed regarding the effects of exercise for patients with metastatic breast cancer. The results of the PREFERABLE-EFFECT trial...
Families of Men With Subfertility May Have Increased Risk of Several Types of Cancers
Investigators have found that the families of subfertile men may have a higher risk of developing certain types of cancers at younger ages compared with the families of fertile men, according to a recent study published by Ramsay et al in Human Reproduction. Background Previous research has shown...
Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma
The chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel may offer benefit in patients with multiple myeloma who experienced disease progression or relapse following initial therapy, according to new findings presented by Hillengass et al at the 2024 Tandem Meetings:...
AACR Cancer Centers Alliance Formed
Under the leadership of preeminent U.S. cancer center directors, the American Association for Cancer Research (AACR) recently announced the formation of an innovative initiative, the AACR Cancer Centers Alliance. The Alliance will bring together the nation’s cancer centers, with the goal of...
Exploring the Role of Intravenous Mistletoe Extract in Treating Metastatic Solid Tumors
Guest Editor’s Note: The use of mistletoe extract to support systemic therapy and improve quality of life for patients with cancer, though common, remains controversial. Promising results have been reported, but largely in trials that were not placebo-controlled nor properly randomized. In this...
ASCO Remembers Humanitarian and Health Equity Champion Edith P. Mitchell, MD
ASCO is deeply saddened by the death of oncology luminary, health equity champion, and ASCO Humanitarian Award honoree Edith P. Mitchell, MD, MACP, FCCP, FRCP (London), on January 21, 2024. At the time of her passing, Dr. Mitchell was Director of the Center to Eliminate Cancer Disparities,...
Preventing Cancer Should Not Mean Sacrificing Quality of Life
My family first suspected we might have inherited the BRCA1/2 gene mutation after my father was diagnosed with his third cancer, colorectal cancer, following multiple bouts of squamous cell carcinoma and basal cell carcinoma beginning in his 30s and later prostate cancer. But the high risk of...
Belzutifan: New Standard in Previously Treated Renal Cell Carcinoma
Belzutifan is a first-in-class, oral hypoxia-inducible factor (HIF)-2α inhibitor, and active HIF-2α is a key oncogenic driver in clear cell renal cancer. The manufacturer has filed a new drug application for the treatment of adults with RCC who experienced disease progression after PD-1/PD-L1– and...
Evaluating the Use of Perioperative Chemoimmunotherapy in Resectable Gastric and Gastroesophageal Junction Cancers
Updates of two key phase III trials presented at the 2024 ASCO Gastrointestinal Cancers Symposium showed the benefit of adding a checkpoint inhibitor to standard perioperative chemotherapy with FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel) in locally advanced, resectable gastric and...
For Unresectable Liver Cancer, the Addition of Durvalumab and Bevacizumab Boosts Efficacy of Transarterial Chemoembolization
Patients with unresectable hepatocellular carcinoma derived significant benefit from the addition of the monoclonal antibody durvalumab and the angiogenesis inhibitor bevacizumab to transarterial chemoembolization (TACE), which alone has been a standard of care for 20 years. Investigators of the...
Understanding Risk Stratification in Monoclonal Gammopathy of Undetermined Significance
About 4 years ago, I [Jo Cavallo] wrote about the death of my brother Dom from multiple myeloma in 2011 and my subsequent enrollment in the PROMISE trial (ClinicalTrials.gov identifier NCT03689595). My goal for enrolling in the study was twofold: to honor Dom and others with the cancer and to make ...
First-Line Radioligand-Based Therapy Demonstrates Benefit in Some Neuroendocrine Tumors
Adding the radioligand lutetium-177 dotatate (Lu-177 dotatate) to standard therapy almost tripled the median progression-free survival in patients with untreated, high-grade, gastroenteropancreatic neuroendocrine tumors in the randomized phase III NETTER-2 study, researchers reported at the 2024...
NIH’s New Cancer Screening Research Network Could Help Determine Effective Cancer Screening Technologies
The National Institutes of Health (NIH) has launched the Cancer Screening Research Network, a clinical trials network to evaluate emerging cancer screening technologies. The new network will support the Biden-Harris Administration’s Cancer Moonshot initiative by investigating how to identify cancer ...
Prophylactic Oral Vancomycin May Prevent C Difficile Infections, Raise Risk of Gram-Negative Bacteremia in Stem Cell Transplant Recipients
Preventive use of the oral antibiotic vancomycin may be effective at reducing the risk of Clostridioides difficile infections but may increase the risk of gram-negative bacteremia in stem cell transplant recipients, according to new findings presented by Vartanov et al at the 2024 Tandem Meetings:...
Rapid Guideline Update on Radiotracers for Determining Radioligand Treatment Eligibility in Metastatic Castration-Resistant Prostate Cancer
ASCO has released a guideline rapid recommendation update addressing radiotracers used for prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) diagnostic imaging for selecting patients with metastatic castration-resistant prostate cancer (mCRPC) to receive...
ASCO Welcomes New Rule Establishing Electronic Prior Authorization in Federal Health Plans
On January 17, the Centers for Medicare & Medicaid Services (CMS) issued its rule requiring federal health plans—including Medicare Advantage plans, Medicaid plans, and Qualified Health Plans (QHP) on Federally Facilitated Exchanges (FFEs)—to establish an electronic prior authorization process...
Annual Report to the Nation, Part 2: New Cancer Diagnoses Fell Abruptly Early in the COVID-19 Pandemic
New diagnoses of six major cancer types in the United States fell abruptly in early 2020, coinciding with the start of the COVID-19 pandemic, according to findings from part 2 of the latest Annual Report to the Nation on the Status of Cancer.1 The volume of pathology reports also declined sharply...
FDA Approves Biweekly Teclistamab Dosing Regimen for Patients With Multiple Myeloma
On February 20, the U.S. Food and Drug Administration (FDA) approved the supplemental biologics license application for teclistamab-cqyv (Tecvayli) for a reduced dosing frequency of 1.5 mg/kg every 2 weeks in patients with relapsed or refractory multiple myeloma who have achieved and maintained a...
Strategies to Reduce Burden of Colorectal Cancer in Latin America
Investigators may have identified colorectal cancer screening programs in Latin America, according to a recent systematic review and meta-analysis published by Montalvan-Sanchez et al in JAMA Network Open. Background Colorectal cancer—the second leading cause of cancer-related mortality...
Does Annual Breast Cancer Screening Starting at Age 40 Offer Benefit?
Investigators have found that annual breast cancer screening beginning at age 40 and continuing to at least 79 may result in the greatest reduction in mortality with minimal risks, according to a recent study published by Monticciolo et al in Radiology. Background Breast cancer is the second most...
Does Risk-Reducing Mastectomy Reduce the Risk of Breast Cancer—and Mortality?
Investigators have found that risk-reducing mastectomy decreases the risk of receiving a breast cancer diagnosis and the likelihood of mortality in female patients with BRCA1 or BRCA2 genetic variants, according to a recent study published by Metcalfe et al in the British Journal of Cancer....
Modified Chemotherapy Regimens May Improve Quality of Life in Older Patients With Advanced Cancer
Reducing doses and adjusting chemotherapy schedules in older patients with advanced cancer may help improve treatment tolerability without compromising its efficacy, according to a recent study published by Mohamed et al in JAMA Network Open. Background Standard chemotherapy regimens—mostly based...
FDA Approves Osimertinib With Chemotherapy for EGFR-Mutated NSCLC
On February 16, the U.S. Food and Drug Administration (FDA) approved osimertinib (Tagrisso) with platinum-based chemotherapy for patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an...
FDA Grants Accelerated Approval to Lifileucel for Unresectable or Metastatic Melanoma
On February 16, the U.S. Food and Drug Administration (FDA) granted accelerated approval to lifileucel (Amtagvi), a tumor-derived autologous T-cell immunotherapy, for adult patients with unresectable or metastatic melanoma who were previously treated with a PD-1 blocking antibody, or, if they have...
Neoadjuvant Chemotherapy May Benefit Patients With Penile Squamous Cell Carcinoma
Researchers have found that neoadjuvant chemotherapy may be safe and effective in patients with locally advanced penile squamous cell carcinoma, according to a recent study published by Rose et al in the Journal of the National Cancer Institute. The findings may help address a critical gap in...
Ablative Stereotactic Magnetic Resonance–Guided Adaptive Radiation Therapy for Pancreatic Ductal Adenocarcinoma
Researchers have found that ablative stereotactic magnetic resonance (MR)-guided adaptive radiation therapy may improve local control and overall survival in patients with borderline resectable and locally advanced pancreatic ductal adenocarcinoma, according to a recent study published by Chuong et ...
FDA Approves Tepotinib for Metastatic NSCLC
On February 15, the U.S. Food and Drug Administration (FDA) granted traditional approval to the kinase inhibitor tepotinib (Tepmetko) for adult patients with metastatic non–small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14–skipping alterations. The agent is...
Expert Point of View: David A. Sallman, MD, and Mikkael A. Sekeres, MD
Two experts in myelodysplastic syndromes (MDS) discussed the findings on the combination of venetoclax plus azacitidine in the treatment of higher-risk MDS with The ASCO Post. David A. Sallman, MD, Assistant Member in the Department of Malignant Hematology, Moffit Cancer Center, Tampa, provided...
Venetoclax Plus Azacitidine Evaluated in High-Risk Myelodysplastic Syndromes
For the treatment of high-risk, treatment-naive myelodysplastic syndromes (MDS), the regimen of venetoclax plus azacitidine led to high response rates, durable responses, and encouraging overall survival, in a phase Ib study reported at the 2023 American Society of Hematology (ASH) Annual Meeting...
Expert Point of View: Prithviraj Bose, MD
Prithviraj Bose, MD, Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, shared his thoughts on MANIFEST-2 and TRANSFORM-1 with The ASCO Post. While both were international phase III trials that showed similar benefits with two different...
Expert Point of View: Dipenkumar Modi, MD
The ASCO Post obtained comments on the Smart Stop study from Dipenkumar Modi, MD, a medical oncologist and hematologist at the Barbara Ann Karmanos Cancer Institute and Assistant Professor of Oncology at Wayne State University School of Medicine, Detroit. Dr. Modi applauded the investigators for...
Steven A. Rosenberg, MD, PhD, Honored With 2024 AACR Award for Lifetime Achievement in Cancer Research
The American Association for Cancer Research (AACR) will award Steven A. Rosenberg, MD, PhD, Fellow of the AACR Academy, with the 2024 AACR Award for Lifetime Achievement in Cancer Research during the AACR Annual Meeting, to be held April 5–10 in San Diego. His award lecture will be presented on...
Expert Point of View: Ajay K. Nooka, MD, MPH, and Dan Vogl, MD, MSCE
Ajay K. Nooka, MD, MPH, Professor in the Department of Hematology and Medical Oncology at Emory University, and Dan Vogl, MD, MSCE, Associate Professor of Medicine at the Hospital of the University of Pennsylvania, shared their thoughts on the PERSEUS trial for The ASCO Post. Dr. Nooka noted that ...
Expert Point of View: Michael Crump, MD
Michael Crump, MD, of the Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre, Toronto, expressed some concerns about the study presented by Shadman et al in patients with large B-cell lymphoma (LBCL). “These data should be interpreted with caution. The patient...
Expert Point of View: Peter Voorhees, MD
Peter Voorhees, MD, a multiple myeloma specialist at Levine Cancer Institute and Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Durham, North Carolina, introduced the plenary presentation of the phase III IsKia trial by Gay et al and further commented on the study for The ASCO...
Expert Point of View: William G. Blum, MD and Mikkael Sekeres, MD, MS
Thoughts on the study by Othman et al were provided by William G. Blum, MD, Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine and Director of the Acute Leukemia Program at Winship Cancer Institute, and Mikkael Sekeres, MD, MS, Professor of...
PERSEUS: Daratumumab Regimen Significantly Improves Progression-Free Survival in Newly Diagnosed Multiple Myeloma
The addition of the CD38 monoclonal antibody daratumumab to a standard regimen for patients with newly diagnosed transplant-eligible multiple myeloma significantly prolonged progression-free survival vs standard treatment in the phase III PERSEUS trial. The study was reported as a late-breaking...
STAb T-Cell–Based Immunotherapy in Multiple Myeloma
A novel immunotherapy based on STAb T cells may be more effective at treating multiple myeloma than chimeric antigen receptor (CAR) T-cell therapy, according to a recent study published by Díez-Alonso et al in Science Translational Medicine. Background Multiple myeloma is the second most common...
Racial Representation Affects Trust for Black Patients Seeking Prostate Cancer Information Online
Among Black patients with prostate cancer, racial representation may be a key factor affecting their trust in websites offering information on the disease, according to a recent study published by Loeb et al in The Journal of Urology. Background Black men may have higher rates of prostate cancer...
Triplet for Advanced HER2-Negative Breast Cancer
A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research published by Roussos Torres et al in Nature Cancer. The regimen included a histone deacetylase (HDAC) inhibitor combined with two types of checkpoint...
Understanding the Discordance About Prognosis Between Clinicians and Terminally Ill Patients and Their Surrogates
Research shows that about half of adults near the end of life in the United States are too ill to participate in decisions about whether to accept life-prolonging treatment,1 requiring family members and other proxies to serve as surrogate decision-makers for their critically ill loved ones....
Durvalumab Plus Ceralasertib in Patients With Immunotherapy-Resistant NSCLC
The combination of the anti–PD-L1 antibody durvalumab and the ATR kinase inhibitor ceralasertib may help overcome inherent immune resistance and reinvigorate antitumor activity in patients with advanced non–small cell lung cancer (NSCLC), according to a recent study published by Besse et al in...
Neoadjuvant Immunotherapy May Improve Long-Term Survival in Patients With Resectable Soft-Tissue Sarcoma
Patients with soft-tissue sarcoma treated with neoadjuvant immunotherapy had very little residual tumor at the time of surgery and promising long-term survival, according to phase II trial results published by Roland et al in Nature Cancer. Background About 13,000 new cases of soft-tissue...
FDA Approves Irinotecan Liposome as First-Line Treatment of Metastatic Pancreatic Adenocarcinoma
On February 13, the U.S. Food and Drug Administration (FDA) approved irinotecan liposome (Onivyde) with oxaliplatin, fluorouracil, and leucovorin for the first-line treatment of metastatic pancreatic adenocarcinoma. NAPOLI-3 Efficacy was evaluated in NAPOLI-3 (ClinicalTrials.gov identifier...
